Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

Blood

Volumn 125, Issue 8, 2015, Pages 1333-1338

  Holtan, Shernan G ^a   DeFor, Todd E ^b   Lazaryan, Aleksandr ^a   Bejanyan, Nelli ^a   Arora, Mukta ^a   Brunstein, Claudio G ^a   Blazar, Bruce R ^a   MacMillan, Margaret L ^a   Weisdorf, Daniel J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; DEATH; DONOR; FEMALE; GRAFT VERSUS HOST DISEASE FREE RELAPSE FREE SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HEMATOPOIETIC CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RELAPSE; SURVIVAL; UMBILICAL CORD BLOOD; ADOLESCENT; ADVERSE EFFECTS; AGED; ALLOTRANSPLANTATION; CHILD; DISEASE FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; RECURRENT DISEASE; RETROSPECTIVE STUDY; UNRELATED DONORS; YOUNG ADULT;

BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; BIOMARKERS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; YOUNG ADULT;

EID: 84923348954     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-10-609032     Document Type: Article

References (21)

1. Sehn LH, Alyea EP, Weller E, et al. Comparative outcomes of T-cell-depleted and non-T-celldepleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999; 17(2):561-568.
2. Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117(25): 6963-6970.
3. Alyea E, Neuberg D, Mauch P, et al. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002;8(3):139-144.
4. Sankoh AJ, Li H, D'Agostino RB Sr. Use of composite endpoints in clinical trials. Stat Med. 2014;33(27):4709-4714.
5. Bolanos-Meade J, Koreth J, Reshef R. A multicenter phase II trial randomizing novel approaches for graft-versus-host disease prevention compared to contemporary controls (1203). Available at: https://clinicaltrials.gov/ct2/show/NCT02208037. Accessed January 19, 2015.
6. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8): 2912-2919.
7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
8. Cox DR. Regression models and life tables. J R Stat Soc, B. 1972;34:187-220.
9. Collet D. Modelling Survival Data in Medical Research, 2nd ed. London: Chapman & Hall; 2003.
10. Zhang X, Loberiza FR, Klein JP, Zhang MJ. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed. 2007;88(2):95-101.
11. Gail MH, Byar DP. Variance calculations for direct adjusted survival curves, with applications to testing for no treatment effect. Biom J. 1986;28:587-599.
12. Andersen PK, Klein JP, Knudsen KM, Tabanera y Palacios R. Estimation of variance in Cox's regression model with shared gamma frailties. Biometrics. 1997;53(4):1475-1484.
13. Hougaard P. Frailty models for survival data. Lifetime Data Anal. 1995;1(3):255-273.
14. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2013. Available at: http://www.cibmtr.org. 2013.
15. Anderson D, DeFor T, Burns L, et al. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graftversus-host disease and infections. Biol Blood Marrow Transplant. 2003;9(1):52-59.
16. Anasetti C, Logan BR, Lee SJ, et al; Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012; 367(16):1487-1496.
17. Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant. 2007; 13(12):1461-1468.
18. Bayraktar UD, de Lima M, Saliba RM, et al. Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2013;19(6):898-903.
19. Weisdorf D, Eapen M, Ruggeri A, et al. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. Biol Blood Marrow Transplant. 2014; 20(6):816-822.
20. Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010;116(22):4693-4699.
21. Danby R, Rocha V. Improving engraftment and immune reconstitution in umbilical cord blood transplantation. Front Immunol. 2014;5:68.